Cisco on Deck: What...
Health Care: Drugs
Santarus Inc. (SNTS: NASDAQ)
$4.71 -0.30 | -5.99%
02/08/12 - 04:00 PM ET
419.39K / 332.50K
Vol / Avg. Vol:5.01 / 5.01
Open / Prev. Close:4.64 - 5.02
Today's Range:2.40 - 5.10
52 Wk Range:42.30%
Performance YTD:TheStreet Rating:
Portfolios with SNTS
- Portfolio NameUser Type
- ContributorStocks At New 52-Week Highs...
- UserJust Learning ao926
- UserJust Learning
- ContributorDollar Store
- Userbetterlatethannever
- UserRAPTOR SPRTD-1102092204
- Usergburr Portfolio 1
- Userpetomm8 Portfolio 1
- UserPANTERA GROUP 168
- UserSUPRATRADE RED-0209070106
Latest SNTS Headlines from TheStreet
- 5 Stocks Hitting New 52-Week Highs 01.11.12 | 02:01 pm
- Santarus' CEO Discusses Business Update Conference Call Transcript 12.22.11 | 12:12 pm
- Santarus' CEO Hosts Business Update Conference Call (Transcript) 12.22.11 | 12:12 pm
- Santarus' CEO Discusses At Lazard Capital Markets 8th Annual Healthcare - Conference Call Transcript 12.02.11 | 11:12 am
- Santarus' CEO Presents At Lazard Capital Markets 8th Annual Healthcare Conference - Event Transcript 12.02.11 | 11:12 am
- Santarus Inc. Stock Upgraded (SNTS) 11.15.11 | 06:11 am
- Santarus' CEO Discusses Q3 2011 Results - Earnings Call Transcript 11.07.11 | 09:11 pm
- Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript 09.20.11 | 07:09 pm
- Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript 08.03.11 | 11:08 pm
- Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript 05.04.11 | 10:05 pm
Press Releases for SNTS
- Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE - Business Wire 02.06.12 | 04:02 am
- Santarus Adds FENOGLIDE To Marketed Products Portfolio - Business Wire 12.21.11 | 04:12 pm
- Santarus Submits New Drug Application To FDA For UCERIS (budesonide) Tablets - Business Wire 12.20.11 | 04:12 pm
- Santarus And Pharming Announce Oral Presentations Of Retrospective Analyses Of Data From RHUCIN Clinical Program At World Allergy Congress - Business Wire 12.07.11 | 01:12 am
- Santarus Announces Presentation Of New Open-Label UCERIS (Budesonide) Data At The Crohn’s And Colitis Foundation Clinical & Research Conference - Business Wire 12.01.11 | 04:12 am
- Santarus To Present At November Investment Conferences - Business Wire 11.08.11 | 04:11 am
- Santarus Reports Third Quarter 2011 Financial Results - Business Wire 11.07.11 | 04:11 pm
- Santarus And Pharming Announce Presentation Of Retrospective Analyses Of Data From Clinical Studies Of RHUCIN - Business Wire 11.04.11 | 02:11 am
- Santarus Announces Presentation Of Pooled Data From Budesonide MMX Phase III Clinical Studies At The ACG Annual Scientific Meeting - Business Wire 11.01.11 | 04:11 am
- Santarus To Hold Third Quarter 2011 Financial Results Conference Call On November 7 - Business Wire 10.26.11 | 04:10 am
Partner Headlines for SNTS
- Most Volatile Stocks on Earnings Report Days - Seeking Alpha 01.07.11 | 07:01 pm
- UPDATE 1-Santarus files for approval of anti-swelling drug - Reuters 12.28.10 | 09:12 am
- Santarus' Q3 Loss: The Rough Path to Recovery - Seeking Alpha 11.09.10 | 09:11 am
- UPDATE 1-Santarus posts Q3 loss, lowers FY revenue view - Reuters 11.08.10 | 05:11 pm
- Healthcare Headlines: Santarus Rallies, Amgen Announces Results - Seeking Alpha 10.06.10 | 08:10 am
- UPDATE 1-Santarus' anti-inflammatory drug meets late-stage goal - Reuters 09.29.10 | 05:09 pm
- Santarus: A Stock With Potential to Run - Seeking Alpha 09.21.10 | 08:09 am
- UPDATE 1-Santarus Q2 beats Street, shares rise - Reuters 08.02.10 | 05:08 pm
- Rifamycin Enrollment Commences - Analyst Blog - Zacks 06.04.10 | 04:06 pm
- UPDATE 1-Santarus says appeals court ruling in Par patent suit - Reuters 05.14.10 | 06:05 pm
